Talarozole

• CAT Number: I002545
• CAS Number: 201410-53-9
• Molecular Formula: C21H23N5S
• Molecular Weight: 377.51
• Purity: ≥95%
• Synonyms: N-[4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine
• Target: RARs
• Solubility: DMSO: ≥ 36 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)
• InChIKey: SNFYYXUGUBUECJ-UHFFFAOYSA-N
• SMILES: CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4

Talarozole（Cat No.:I002545）is a selective inhibitor of the enzyme cytochrome P450 26 (CYP26), responsible for the degradation of retinoic acid, a metabolite of vitamin A involved in cellular differentiation and proliferation. By inhibiting CYP26, talarozole increases retinoic acid levels, enhancing its biological effects. This mechanism makes talarozole a promising candidate for treating skin disorders like psoriasis and acne, where retinoic acid plays a key role in skin health. It has also been explored for its potential in cancer therapy and other retinoid-responsive diseases. Talarozole’s selective action offers a novel approach in retinoid-based therapies.

Reference

[1]. Pavez Loriè E, Cools M, Borgers M, Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br J Dermatol. 2009 Jan;160(1):26-36.
[2]. Geria AN, Scheinfeld NS. Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Curr Opin Investig Drugs. 2008 Nov;9(11):1228-37.
[3]. Baert B, De Spiegeleer B. Local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. Skin Pharmacol Physiol. 2011;24(3):151-9.